These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7964811)

  • 41. Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review.
    Montané E; Vallano A; Laporte JR
    Neurology; 2004 Oct; 63(8):1357-63. PubMed ID: 15505149
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The use of sirdalud MR in patients with multiple sclerosis].
    Batysheva TT; Popova NF; Petrov SV; Kamchatnov PR; Zaĭtsev KA; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 1):57-60. PubMed ID: 21322181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The use of sirdalud in painful muscle tonic syndromes].
    Damulin IV
    Ter Arkh; 1997; 69(10):68-72. PubMed ID: 9471796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tizanidine in chronic tension-type headache: a placebo controlled double-blind cross-over study.
    Fogelholm R; Murros K
    Headache; 1992 Nov; 32(10):509-13. PubMed ID: 1468911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Spasticity: current and future management. Royal College of Physicians, November 13, 1997.
    Hosp Med; 1998 Jan; 59(1):61-9. PubMed ID: 9798568
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tizanidine for alcohol withdrawal treatment.
    Bou Khalil R
    Med Hypotheses; 2011 Oct; 77(4):548-9. PubMed ID: 21733633
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Myorelaxant effect after intrathecal injection of antispastic drugs in rats.
    Klockgether T; Schwarz M; Wüllner U; Turski L; Sontag KH
    Neurosci Lett; 1989 Feb; 97(1-2):221-6. PubMed ID: 2919005
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review.
    Taricco M; Pagliacci MC; Telaro E; Adone R
    Eura Medicophys; 2006 Mar; 42(1):5-15. PubMed ID: 16565680
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spasmodic torticollis: treatment with Tizanidine.
    ten Houten R; Lakke JP; de Jong P; van Weerden TW; van den Burg W; Wesseling H
    Acta Neurol Scand; 1984 Nov; 70(5):373-6. PubMed ID: 6391067
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
    Henney HR; Shah J
    Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term efficacy and safety of incobotulinumtoxinA and conventional treatment of poststroke arm spasticity: a prospective, non-interventional, open-label, parallel-group study.
    Dressler D; Rychlik R; Kreimendahl F; Schnur N; Lambert-Baumann J
    BMJ Open; 2015 Dec; 5(12):e009358. PubMed ID: 26719317
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
    Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury.
    Nance PW; Huff FJ; Martinez-Arizala A; Ayyoub Z; Chen D; Bian A; Stamler D
    Spinal Cord; 2011 Sep; 49(9):974-80. PubMed ID: 21577221
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness comparison of tizanidine and baclofen in the management of spasticity.
    Rushton DN; Lloyd AC; Anderson PM
    Pharmacoeconomics; 2002; 20(12):827-37. PubMed ID: 12236804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modified release tizanidine: a review.
    Hutchinson DR
    J Int Med Res; 1989; 17(6):565-73. PubMed ID: 2697626
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Protocol for tizanidine use in infantile cerebral palsy].
    Palazón García R; Benavente Valdepeñas A; Arroyo Riaño O
    An Pediatr (Barc); 2008 May; 68(5):511-5. PubMed ID: 18448000
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation of the transmission in group II heteronymous pathways by tizanidine in spastic hemiplegic patients.
    Maupas E; Marque P; Roques CF; Simonetta-Moreau M
    J Neurol Neurosurg Psychiatry; 2004 Jan; 75(1):130-5. PubMed ID: 14707322
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
    Backman JT; Granfors MT; Neuvonen PJ
    Eur J Clin Pharmacol; 2006 Jun; 62(6):451-61. PubMed ID: 16758262
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: a single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects.
    Henney HR; Fitzpatrick A; Stewart J; Runyan JD
    Clin Ther; 2008 Dec; 30(12):2263-71. PubMed ID: 19167586
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The use of sirdalud in the treatment of spasticity in infantile cerebral palsy].
    Maksimov OG; Secheĭko MV; Andriĭchuk EL
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(3):22-3. PubMed ID: 10205837
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.